Watchlist Price Alert

ACADIA Pharmaceuticals In... (ACAD)

NASDAQ: ACAD · Real-Time Price · USD

22.45

-0.26 (-1.14%)

At close: Jun 23, 2025, 3:59 PM

22.48

0.16%

Pre-market: Jun 24, 2025, 05:44 AM EDT

-1.14% (1D)

Bid	22.22
Market Cap	3.76B
Revenue (ttm)	996.28M
Net Income (ttm)	228.88M
EPS (ttm)	1.37
PE Ratio (ttm)	16.38
Forward PE	26.7
Analyst	Buy

Ask	23.4
Volume	991,823
Avg. Volume (20D)	2,141,495
Open	23.04
Previous Close	22.71
Day's Range	22.04 - 23.04
52-Week Range	13.40 - 25.23
Beta	0.65

About ACAD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ACAD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ACAD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

ACADIA Pharmaceuticals Inc. is scheduled to release its earnings on Aug 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+26.48%

ACADIA Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

1 month ago

+14.31%

ACADIA Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.

News

5 days ago · zacks.com

KMDA vs. ACAD: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attract...

6 days ago · businesswire.com

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducem...

2 weeks ago · businesswire.com

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for ...

2 weeks ago · zacks.com

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

2 weeks ago · businesswire.com

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June...

3 weeks ago · businesswire.com

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Mond...

3 weeks ago · businesswire.com

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role All...

1 month ago · zacks.com

GSK or ACAD: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attra...